Longeveron (LGVN) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenues: $0.4 million for Q1 2026, consistent with Q1 2025, comprising $0.4 million in clinical trial revenue and $20,000 in contract manufacturing revenue.

Clinical Trial Revenue: Increased by 46% year-over-year due to higher participant demand for the Bahamas Registry Trial.

Contract Manufacturing Revenue: Decreased by 84% year-over-year, attributed to reduced demand from third-party clients.

Expenses:

General and Administrative: $2.7 million (down 7% from $2.9 million in Q1 2025).

Research and Development: $2.3 million (down 8% from $2.5 million in Q1 2025).

Net Loss: $4.7 million, a 6% decrease from $5 million in Q1 2025.

Cash Position: $15.8 million as of March 31, 2026, expected to fund operations into Q4 2026.

2Strategic Updates and Business Highlights

Leadership Transition: Stephen Willard appointed as CEO in February 2026, initiating a comprehensive review of assets and strategic planning.

Investment Attraction: Successfully secured new capital from notable life sciences investment funds, enhancing financial stability.

Strategic Focus: Transitioning to a capital-efficient, asset-light model with an emphasis on strategic licensing partnerships for laromestrocel across various programs (HLHS, Alzheimer's, PDCM, Aging-related Frailty).

Upcoming Events: Participation in the BIO International Convention in June 2026 to explore partnerships for stem cell development programs.

3Forward Guidance and Outlook

Clinical Milestones: Anticipating top-line results from the ELPIS II Phase IIb trial for HLHS in August 2026, which is viewed as a critical inflection point for the company.

Regulatory Engagement: Plans to engage with the FDA post-results to discuss potential pathways for a Biological License Application (BLA).

Future Studies: Preparations for a Phase II trial for Pediatric Dilated Cardiomyopathy (PDCM) expected to initiate in 2027.

4Bad News, Challenges, or Points of Concern

Regulatory Feedback: The FDA indicated that the primary endpoint of right ventricular ejection fraction (RVEF) in the ELPIS II trial is not appropriate for demonstrating efficacy, complicating the trial's pivotal status.

Dependence on ELPIS II Results: The company's future trajectory heavily relies on the outcomes of the ELPIS II trial, which introduces significant uncertainty.

Contract Manufacturing Decline: A sharp decrease in contract manufacturing revenue raises concerns about the sustainability of this revenue stream.

5Notable Q&A Insights

Regulatory Strategy Post-ELPIS II: The company plans to request a Type C meeting with the FDA immediately after the ELPIS II results are released, with potential for a Type B meeting if results are positive.

Post-Marketing Requirements: If approved, long-term studies on transplant-free survival will likely be required, as discussed with the FDA.

Impact on PDCM Program: While HLHS and PDCM are distinct, insights from HLHS may inform the PDCM program, although specific endpoints have already been agreed upon with the FDA.

Compassionate Use: The company is open to discussing compassionate use for placebo patients post-ELPIS II, emphasizing their commitment to patient access. Overall, Longeveron is navigating a pivotal period with strategic repositioning and upcoming clinical milestones, while facing regulatory challenges that could impact its development programs.